DDInter1716 DDInter1376
Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Succinylcholine {u} (Compound) resembles {v} (Compound) Carbachol
Succinylcholine {u} (Compound) resembles {v} (Compound) Decamethonium
Succinylcholine {u} (Compound) binds {v} (Gene) CHRND
Succinylcholine {u} (Compound) is included by {v} (Pharmacologic Class) Neuromuscular Depolarizing Blockade
Succinylcholine {u} (Compound) causes {v} (Side Effect) Respiratory failure
Succinylcholine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Irinotecan
Succinylcholine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Physostigmine
Succinylcholine {u} may lead to a major life threatening interaction when taken with {v} Neomycin
Succinylcholine (Compound) resembles Carbachol (Compound)
Succinylcholine (Compound) resembles Decamethonium (Compound)
Succinylcholine (Compound) binds CHRND (Gene)
Succinylcholine (Compound) is included by Neuromuscular Depolarizing Blockade (Pharmacologic Class)
Succinylcholine (Compound) causes Respiratory failure (Side Effect)
Succinylcholine may cause a minor interaction that can limit clinical effects when taken with Irinotecan
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Succinylcholine may lead to a major life threatening interaction when taken with Neomycin